Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > June 30, 2022
Daily News
June 30, 2022
- Despite 4 Trillion Yen Debt, Takeda CEO Confident in Deleveraging, Pipeline Boost, Shareholder Returns
June 30, 2022
- Pfizer Seeks Japan Approval of Aplastic Anemia Med
June 30, 2022
- Survey Finds 11.7% of Wholesaler Transactions Negotiated through Proxies: MHLW
June 30, 2022
- Tissue-Engineering Market in Asia to Hit 712 Billion Yen in 2030: Fuji Keizai
June 30, 2022
- Japan Begins TPOXX Clinical Research as It Braces for Monkeypox Outbreak
June 30, 2022
- Takeda CEO’s Pay Down to 1.86 Billion Yen in FY2021
June 30, 2022
- Generic Use Rate Stands at 79.5% in FY2021: JGA
June 30, 2022
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…